DDInter336 DDInter706
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available.
Celecoxib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Digoxin
Digoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Exenatide
Celecoxib {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Digoxin
Digoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Exenatide
Celecoxib {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is downregulated by {v} (Compound) Digoxin
Digoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Exenatide
Celecoxib {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Meclofenamic acid
Meclofenamic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Celecoxib {u} (Compound) causes {v} (Side Effect) Thrombocytopenia
Thrombocytopenia {u} (Side Effect) is caused by {v} (Compound) Digoxin
Digoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Exenatide
Celecoxib {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Conjugated estrogens
Conjugated estrogens {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Celecoxib {u} (Compound) causes {v} (Side Effect) Drug interaction
Drug interaction {u} (Side Effect) is caused by {v} (Compound) Ofloxacin
Ofloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Celecoxib {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is downregulated by {v} (Compound) Danazol
Danazol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Celecoxib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Danazol
Danazol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Celecoxib {u} (Compound) causes {v} (Side Effect) Thrombocytopenia
Thrombocytopenia {u} (Side Effect) is caused by {v} (Compound) Danazol
Danazol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Celecoxib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Digoxin (Compound) and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Celecoxib (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Digoxin (Compound) and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Celecoxib (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is downregulated by Digoxin (Compound) and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Celecoxib (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Meclofenamic acid (Compound) and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Celecoxib (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Digoxin (Compound) and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Celecoxib (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Conjugated estrogens (Compound) and Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Celecoxib (Compound) causes Drug interaction (Side Effect) and Drug interaction (Side Effect) is caused by Ofloxacin (Compound) and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Celecoxib (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is downregulated by Danazol (Compound) and Danazol may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Celecoxib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Danazol (Compound) and Danazol may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Celecoxib (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Danazol (Compound) and Danazol may cause a moderate interaction that could exacerbate diseases when taken with Exenatide